NCT04445532

Hepatobiliary Tumors Tissue Samples Acquisition

Acquisition of Blood and Tumor Tissue Samples From Patients With Hepatobiliary Tumors

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 450 (estimated)
• Sponsor: Peking Union Medical College Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

Hepatobiliary tumors have a poor prognosis and high individual heterogeneity, so it is of great significance to find important prognostic markers and then screen out specific subgroups of people; meanwhile, chronic hepatitis, cirrhosis, and healthy control participants also need to show the evolution of tumors and discover specific diagnostic markers as a control group. Moreover, targeted therapy and immunotherapy make cancer treatment enter a new field, but only part of patients achieve response rates and reach clinical benefit. However, these drugs are expensive and can cause treatment-related adverse events. Therefore, reliable biomarkers identification is needed to help predict the response to these treatment options in order to screen patients with better responsiveness and avoid wasting money. Multi-omics research can reveal the characteristics of hepatobiliary tumors more deeply and find meaningful therapeutic targets. Therefore, 450 patients at least 18 years of age with hepatobiliary tumors were included in this study.

Detailed description

OBJECTIVES: 1. Observe the biomarkers of resectable hepatobiliary tumor recurrence (DFS) and survival (OS); 2. Observe the evolution of tumors and discover specific diagnostic markers as a control group. 3. Observe the response (ORR), progression (PFS) and survival (OS) biomarkers of targeted immunotherapy for advanced hepatobiliary tumors; 4. To elaborate on the multi-omics study of hepatobiliary tumors, to further subtype and find therapeutic targets

Conditions

• Hepatocellular Carcinoma
• Cholangiocarcinoma
• Gallbladder Cancer
• Biliary Tract Cancer
• Liver Cancer
• Precancerous Condition
• Benign Hepatobiliary Disease
• Healthy, no Evidence of Disease

Interventions

Type	Name	Description
OTHER	Gene expression analysis	Gene expression analysis
OTHER	Genomic analysis	Genomic analysis
OTHER	Protein expression analysis	Protein expression analysis
OTHER	Proteomic profiling	Proteomic profiling
OTHER	Polymerase chain reaction	Polymerase chain reaction
OTHER	Mass spectrometry	Mass spectrometry
OTHER	Immunohistochemistry	Immunohistochemistry
OTHER	Metabolomics profiling	Metabolomics profiling
OTHER	Methylation and epigenetic analysis	Methylation and epigenetic analysis
OTHER	Liquid biopsy analysis	Liquid biopsy analysis, such as cell-free DNA or circulating tumor cell analysis
OTHER	Laboratory biomarker analysis	Laboratory biomarker analysis (such as AFP, CA19-9, CEA)

Timeline

• Start date: 2020-10-11
• Primary completion: 2025-06-01
• Completion: 2025-06-01
• First posted: 2020-06-24
• Last updated: 2023-07-07

Locations

1 site across 1 country: China